Kastel (Ramipril, Rosuvastatin Calcium)

Ramipril and Rosuvastatin calcium, the active ingredients in Kastel, are an ACE inhibitor and an HMG‑CoA reductase inhibitor presented as an oral tablet for oral use. The combination treats hypertension and hyperlipidaemia, helping to lower blood pressure and reduce LDL‑cholesterol in adult patients at cardiovascular risk.\n\nGNH India supplies Kastel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kastel acts on the renin‑angiotensin system and cholesterol synthesis pathway to manage cardiovascular conditions.\n\nHypertension: lowers blood pressure by inhibiting angiotensin‑converting enzyme.\nHyperlipidaemia: reduces LDL‑cholesterol by blocking HMG‑CoA reductase.\nCardiovascular risk reduction: decreases the likelihood of major adverse cardiovascular events when both blood pressure and lipid levels are controlled.

Kastel may cause a range of adverse reactions.\n\nCommon Side Effects:\n- Cough: dry, persistent throat irritation.\n- Dizziness or light‑headedness, especially after the first dose.\n- Headache: mild to moderate intensity.\n- Muscle pain or weakness: often related to the statin component.\n- Gastrointestinal upset: nausea, abdominal discomfort or diarrhoea.\n- Elevated liver enzymes: mild transaminase increase.\n\nSerious or Rare Side Effects:\n- Angioedema: swelling of face, lips, tongue or airway.\n- Rhabdomyolysis: severe muscle breakdown with dark urine.\n- Acute liver injury: jaundice, severe transaminase rise.\n- Hyperkalemia: high serum potassium levels.\n- Acute renal failure: sudden loss of kidney function.\n- Anaphylactic reaction: severe allergic response requiring emergency care.

Before prescribing Kastel, clinicians should consider several safety measures.\n\nMonitor blood pressure: check regularly after therapy initiation.\nAssess renal function: adjust dose in patients with impaired kidneys.\nCheck serum potassium: avoid hyperkalemia, especially with potassium‑sparing agents.\nScreen liver enzymes: monitor for hepatotoxicity during treatment.\nAvoid use in patients with known hypersensitivity to ACE inhibitors or statins.\nStore at ambient temperature: keep in the original container, protect from moisture and light.

Kastel can interact with several medicines, requiring careful management.\n\nMajor Interactions (Avoid):\n- Potassium‑sparing diuretics: increased risk of hyperkalemia.\n- Concomitant ACE inhibitors or ARBs: additive renal effects and hypotension.\n- Strong CYP3A4 inhibitors (e.g., itraconazole): raise rosuvastatin concentrations.\n\nModerate Interactions (Monitor Closely):\n- NSAIDs: may impair renal function when combined with ACE inhibition.\n- Beta‑blockers: can enhance antihypertensive effect, requiring blood pressure monitoring.